What if you could predict how your candidate will perform using lab data? In Vitro-In Vivo Extrapolation (IVIVE) turns this vision into reality by converting in vitro metabolism results into quantitative predictions of human drug clearance. In this guide, we answer seven frequently asked questions about IVIVE so you can use this tool to speed development, cut costs, and improve decision-making across your pipeline.
IVIVE (In Vitro-In Vivo Extrapolation) is an evolving approach that helps researchers estimate how quickly compounds are metabolized and cleared by the human liver. Simply put, it uses lab data to predict real-world outcomes. This is important because drug development is often slow and costly. Using IVIVE to forecast in vivo clearance from in vitro data can help streamline development and reduce expenses.
If you’re a drug developer exploring IVIVE, it helps to understand what it involves and why it matters. That’s why we answered the seven most common questions about IVIVE to help you decide if it’s the right option for your next drug.
Question #1: Why is IVIVE important for drug development?
The IVIVE model takes in vitro data obtained from a relatively simple in vitro metabolic model and uses it to extrapolate rates of metabolism during the early phase of drug discovery. Scientists use IVIVE to better understand and quantify the relationship between external/internal exposure and toxicological response. The results can facilitate drug discovery, product development and chemical risk assessment. IVIVE can also reduce market development risks, shorten turnaround time and save costs during new drug development and validation, improving the efficiency of the entire R&D process.
Key benefits of IVIVE include:
- Reduced development timelines by 30-50%
- Lower preclinical testing costs
- Earlier identification of problematic compounds
- Enhanced regulatory submission support
Question #2: Why not just conduct both in vitro and in vivo studies?
In vitro research is the primary method used in drug discovery because of the high throughput it promises and the rapid results it delivers.In vitro ADME experiments are far less costly and take less time to show results than in vivo ADME experiments, which is why they’re often preferred for new drugs. In vivo research, on the other hand, helps derive pharmacokinetic (PK) profiles of test subjects after administering a drug and can better reflect the relevant characteristics of compounds. IVIVE bridges this gap by combining the cost-effectiveness of in vitro testing with the predictive power needed for in vivo outcomes.
READ MORE: A Guide to In Vitro ADME Testing in Drug Development
Question #3: How does the IVIVE process work step-by-step?
Setting up the IVIVE method requires two important steps. First, you must obtain the in vitro experimental data of liver intrinsic clearance; then, you must establish a correction equation of liver intrinsic clearance rate in vitro. The correction equation is the ultimate goal of IVIVE research, as it’s what allows researchers to accurately predict the in vivo clearance rate.
The IVIVE workflow involves:
- Data Collection: Use commercial compounds with established human PK data
- In Vitro Testing: Measure intrinsic liver clearance using human liver microsomes or hepatocytes
- Correlation Development: Establish linear regression correction equations
- Validation: Apply corrections to predict clearance for new compounds
The predictive model used to establish the relationship between in vitro and in vivo clearance is called the “well-stirred model.” When the measured data of in vivo clearance is known, this IVIVE model can also help calculate the theoretical liver intrinsic clearance in vitro.
Question #4: Which compounds work best for IVIVE studies?
When choosing commercial compounds, make sure liver metabolism is the main route of drug clearance. Your prediction results will be more accurate if the compound’s metabolism is not affected by the proteins used to facilitate biodistribution (i.e., the transporter).
Successful IVIVE studies require compounds where liver metabolism serves as the primary clearance pathway, with minimal transporter effects that could interfere with results. Additionally, compounds should have well-documented human PK data for validation purposes and demonstrate good stability and solubility characteristics for reliable testing.
The ideal IVIVE compound demonstrates straightforward metabolic profiles with well-characterized clearance mechanisms, providing the most reliable foundation for developing accurate correction factors and validation datasets.
Question #5: How accurate are IVIVE predictions?
Despite wide usage and documented success, IVIVE technology is prone to underestimation. IVIVE predictions typically underestimate actual in vivo results with a 3- to 10-fold systematic error. Researchers have worked tirelessly to optimize existing IVIVE models and reduce systematic error, but underestimation still exists, and the mechanism is unclear. The goal is to further optimize the metabolic reaction system in vitro to get corrected in vitro intrinsic clearance and ultimately more accurate IVIVE predictions.
While this systematic bias presents challenges, IVIVE remains valuable for comparative assessments and rank-ordering compounds within development pipelines. The methodology’s consistent bias patterns allow researchers to apply appropriate correction factors and make informed decisions about compound prioritization, even with the inherent limitations.
Question #6: Is there a way to improve predicted data?
Few laboratories have developed assays and data analyses that are advanced enough to accurately predict human clearance. But using an optimization assay called the “well-stirred model” has been shown to improve the accuracy and reliability of experimental data significantly. It is one of the simplest and most widely used predictive models, especially when conducting early screening for new chemical entities. Researchers at WuXi AppTec developed methods that achieved under-prediction of only 1.25-fold for the hepatocyte assay and 3.5-fold for microsome stability assays.
Advanced optimization strategies include:
- Enhanced assay standardization and quality control
- Refined data analysis methods
- Comprehensive validation using diverse compound sets
- Integration with other ADME data
Question #7: Why embark on an IVIVE program?
Developers can use IVIVE to understand and quantify the relationship between external and internal exposure and toxicological response to substances. But predicting clinical utility from preclinical development data is not just scientifically relevant—it makes good business sense. The process is relatively simple and fast, compared to physiologically-based pharmacokinetic modeling and simulation (PBPK) models. It’s also especially suitable for compounds in the early drug discovery phase.
IVIVE programs provide strategic advantages that extend beyond immediate cost savings, enabling faster compound prioritization and selection while reducing development costs and timelines. The methodology also supports better risk assessment for clinical progression and provides bioanalytical data for regulatory submissions. Organizations implementing comprehensive IVIVE programs can achieve competitive advantages through improved resource allocation and reduced development risks.
READ MORE: Early ADME Screening: 3 Ways It Boosts IND Submission Success
Conclusion
IVIVE is a practical and efficient way to predict in vivo clearance rates using in vitro data, but it’s imperative to use the right model to establish an accurate correction factor. The correction formula determines the accuracy of results, so developers who don’t have in-house IVIVE resources to do it accurately should consider working with a testing partner that can.
The key to IVIVE success lies in using validated models and establishing precise correction equations. For developers without in-house IVIVE expertise, partnering with experienced testing providers ensures access to proven methodologies and comprehensive validation support, maximizing the return on your research investment.
WuXi AppTec’s Laboratory Testing Division offers comprehensive IVIVE capabilities with proven methodologies and validation expertise. Our integrated approach combines IVIVE with safety assessment services for broader drug development support and a faster pipeline to clinicals.
Contact our IVIVE specialists today to discuss your specific requirements and discover how optimized In Vitro-In Vivo Extrapolation can accelerate your development timeline.
